About Gary Y. Yang, MD
Dr. Yang is Professor and Dell E. Webb Chair of Radiation Medicine. He also serves as Residency Program Director and Director of Education and Development of Radiation Medicine. He received his medical degree from Chicago Medical School and completed his internship at Yale University followed by residency training at Emory University and fellowship at Johns Hopkins University. Before joining LLU, Yang had served as Residency Program Director and Medical Director of Radiation Medicine at Roswell Park Cancer Institute-SUNY.
Yang has been invited as moderator/faculty speaker at various scientific and educational sessions of international conferences, including the International Society of GI Oncology and the American Society for Radiation Oncology (ASTRO). He was named as “Educator of the Year” by the Association of Residents in Radiation Oncology. The Research Council of America named Yang among “America’s Top Oncologists.” He also was listed among “America’s Top Doctors” by Castle Connelly Medical, Ltd., and was cited as one of the “Best Doctors” by The Best Doctors in America.
In addition to his clinical and research responsibilities, Yang serves as Editor-in-Chief of the Journal of Gastrointestinal Oncology and as Associate Editor of the Journal of Thoracic Disease. He is on the editorial boards of several other oncology journals. He has authored or co-authored more than 150 journal publications, abstracts, and book chapters. He also has been on the committees of ASTRO, the National Comprehensive Cancer Network (NCCN), the Particle Therapy Co-Operative Group (PTCOG) and the Radiation Therapy Oncology Group (RTOG).
At LLU, Yang is responsible for the radiotherapeutic care of patients with gastrointestinal, sarcoma, lymphoma, and prostate cancers. He offers combination treatments, including proton radiation therapy, for patients with these diseases. He collaborates closely with surgical and medical oncologists at LLU in these treatment programs. In addition, Yang has been Principal Investigator for several clinical trials and is actively developing protocols to investigate new approaches to the treatment of GI and other cancers with proton therapy. Among these are:
- Phase II trial of a proton-chemotherapy combination program for locally advanced pancreatic cancer
- Phase II trial of a proton-chemotherapy combination program for resectable esophageal or esophagogastric junction cancer
- Phase I/II trial of stereotactic body proton therapy (SBPT) for patients with liver metastases
- Phase II study of preoperative proton therapy in soft tissue sarcoma